RFG Advisory LLC Purchases 21,962 Shares of Novo Nordisk A/S $NVO

RFG Advisory LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 49.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 66,135 shares of the company’s stock after buying an additional 21,962 shares during the quarter. RFG Advisory LLC’s holdings in Novo Nordisk A/S were worth $3,171,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares in the last quarter. Franklin Resources Inc. grew its holdings in Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after purchasing an additional 717,719 shares during the last quarter. Morgan Stanley increased its position in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after purchasing an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $287,660,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NVO. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a report on Wednesday, August 12th. Finally, BMO Capital Markets restated a “market perform” rating and set a $47.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S Stock Down 1.2%

Novo Nordisk A/S stock opened at $44.62 on Thursday. The firm has a market cap of $199.23 billion, a price-to-earnings ratio of 10.91, a price-to-earnings-growth ratio of 1.52 and a beta of 0.74. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The business’s 50-day moving average price is $47.76 and its 200 day moving average price is $43.68. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion during the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s payout ratio is 20.05%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy moves closer to China launch: Chinese regulators accepted Novo Nordisk’s marketing application for oral Wegovy, opening a potential route into China’s projected $4.46 billion GLP-1 market. Acceptance is an important regulatory step, although approval and commercial success are not guaranteed. Can Oral Wegovy Help Novo Nordisk Capture China’s $4.46 Billion GLP-1 Opportunity?
• Positive Sentiment: Promising pediatric obesity data: A Phase 3 study found weekly semaglutide helped reduce BMI in children with obesity; 40.4% were no longer classified as having obesity after 68 weeks. The results could support future regulatory expansion and create another sizable market for Wegovy. Novo Nordisk’s Semaglutide Meets Goal in Pediatric Obesity Study
• Positive Sentiment: Share repurchases remain supportive: Novo Nordisk’s continuing buyback program provides a source of demand for the stock and may help offset some investor concerns while the company works through its pipeline challenges. Novo Nordisk’s September Tightrope
• Neutral Sentiment: Valuation debate continues: The stock trades well below its 2024 peak, attracting bargain-hunting interest, but investors remain divided over whether the discount adequately reflects slower growth, competition from Eli Lilly and uncertainty surrounding the next generation of obesity medicines.
• Negative Sentiment: Cardiovascular pipeline setback: Novo Nordisk halted two heart-drug trials, weakening confidence in its efforts to diversify beyond diabetes and obesity and prompting at least one analyst rating downgrade. Novo Nordisk: STEP Young Wins, But Heart Trials Just Got Halted
• Negative Sentiment: Competitive and strategic concerns: Novo’s new chief executive has expressed caution about the broader peptide-drug boom, while the company faces an increasingly aggressive obesity-pill race. Those comments reinforce concerns that future growth may require substantial investment and that competitors could pressure pricing and market share.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.